Norrin Antibody
| Code | Size | Price |
|---|
| PSI-5119-0.02mg | 0.02mg | £150.00 |
Quantity:
| PSI-5119-0.1mg | 0.1mg | £449.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Isotype: IgG
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunohistochemistry (IHC)
- Western Blot (WB)
Documents
Further Information
Additional Names:
Norrin Antibody: ND, EVR2, FEVR, Norrin, Norrie disease protein
Application Note:
Norrin antibody can be used for detection of Norrin by Western blot at 1 - 2 μg/mL. Antibody can also be used for immunocytochemistry starting at 5 μg/mL.
Antibody validated: Western Blot in human samples and Immunocytochemistry in human samples. All other applications and species not yet tested.
Antibody validated: Western Blot in human samples and Immunocytochemistry in human samples. All other applications and species not yet tested.
Background:
Norrin Antibody: Norrie disease is an X-linked genetic disorder characterized by progressive atrophy of the eyes, mental disturbances and deafness. The gene responsible for this disease was initially identified through positional cloning. Norrin, the gene product, encodes a small secreted, cysteine-rich protein that is thought to act as a ligand for the Wnt-receptor/beta-catenin signal pathway despite having sequence homology with the Wnt family of proteins. Mice lacking this gene have abnormal blood vessel growth in the vitreous and a disorganized retina; transgenic ectopic expression of Norrin restores normal retinal vasculature. Recent evidence shows that Norrin can attenuate tPA and uPA-mediated death of transformed rat retinal ganglion cells (RGC-5) by activating the Wnt/beta-catenin pathway and regulating the phosphorylation of LRP-1, a cell surface receptor for tPA and uPA, suggesting the Norrin may function in vivo by regulating kinases which may alter the phosphorylation of LRP-1.
Background References:
- Bergen W, Meindl A, van de Pol TJ, et al. Isolation of a candidate gene for Norrie disease by positional cloning. Nat. Genet.1992; 1:199-203.
- Meitinger T, Meindl A, Bork P, et al. Molecular modelling of the Norrie disease protein predicts a cysteine knot growth factor tertiary structure. Nat. Genet.1993; 5:376-80.
- Xu Q, Wang Y, Dabdoub A, et al. Vascular development in the retina and inner ear: control by Norrin and Frizzled-4, a high-affinity ligand-receptor pair. Cell2004; 116:883-95.
- Ohlmann A, Scholz M, Goldwich A, et al. Ectopic norrin induces growth of ocular capillaries and restores normal retinal angiogenesis. J. Neurosci.2005; 25:1701-10.
Buffer:
Norrin Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration:
1 mg/mL
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Homology:
Predicted species reactivity based on immunogen sequence: Bovine: (83%), Mouse: (93%)
Immunogen:
Norrin antibody was raised against an 18 amino acid synthetic peptide from near the amino terminus of human Norrin.
The immunogen is located within the first 50 amino acids of Norrin.
The immunogen is located within the first 50 amino acids of Norrin.
NCBI Gene ID #:
4693
NCBI Official Name:
Norrie disease (pseudoglioma)
NCBI Official Symbol:
NDP
NCBI Organism:
Homo sapiens
Physical State:
Liquid
Protein Accession #:
NP_000257
Protein GI Number:
4557789
Purification:
Norrin Antibody is affinity chromatography purified via peptide column.
Research Area:
Signal Transduction
Swissprot #:
Q00604
User NOte:
Optimal dilutions for each application to be determined by the researcher.
Related Products
| Product Name | Product Code | Supplier | Norrin Peptide | PSI-5119P | ProSci | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|